Teva Sues Mylan, Natco Over Copaxone ANDA

Law360, New York (October 19, 2009, 4:16 PM EDT) -- Teva Pharmaceutical Industries Ltd. has hit Mylan Pharmaceuticals Inc. and Natco Pharma Ltd. with a patent infringement suit over their plans for a generic version of the multiple sclerosis therapy drug Copaxone.

The Israel-based drugmaker gave notice in a statement Friday that it would sue the generic-drug makers in the U.S. District Court for the Southern District of New York, after Teva received notice that Mylan had gotten a Paragraph IV certification in its abbreviated new drug application with the U.S. Food and Drug Administration to...
To view the full article, register now.